Accuray Incorporated Cash Flow Conversion Efficiency

Latest as of June 2026: 0.058x

Accuray Incorporated cash flow conversion efficiency. Based on the latest financial reports, Accuray Incorporated (ARAY) has a cash flow conversion efficiency ratio of 0.058x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.43 Million) by net assets ($41.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Accuray Incorporated (2005–2026)

Cash flow conversion efficiency of Accuray Incorporated from 2005 to 2026. This chart illustrates how Accuray Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ARAY share price today for real-time trading data and today's change.

Accuray Incorporated Cash Flow Conversion Ratio Explained

Accuray Incorporated cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Accuray Incorporated Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Accuray Incorporated ranked by their cash flow conversion efficiency. Also see Accuray Incorporated (ARAY) total market value for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
China Times Publishing Co
TWO:8923
0.071x
Xilam Animation
PA:XIL
0.207x
Passat Société Anonyme
PA:PSAT
0.017x
SMRT Holdings Bhd
KLSE:0117
0.125x
Mighty Kingdom Ltd
AU:MKL
-0.727x
CT AUTOMOTIVE GROUP -005
F:X7X
N/A
Photon Energy N.V.
WAR:PEN
0.119x
Cosmos Exploration Ltd
AU:C1X
-0.171x

Annual Cash Flow Conversion Efficiency for Accuray Incorporated (2005–2026)

The table below shows the annual cash flow conversion efficiency of Accuray Incorporated from 2005 to 2026. Review ARAY free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2026-06-30 $41.70 Million $-6.98 Million -0.167x -575.13%
2025-06-30 $81.17 Million $2.86 Million 0.035x +113.34%
2024-06-30 $45.08 Million $-11.90 Million -0.264x -191.18%
2023-06-30 $53.66 Million $15.54 Million 0.290x +741.79%
2022-06-30 $53.19 Million $-2.40 Million -0.045x -108.07%
2021-06-30 $68.84 Million $38.51 Million 0.559x +2523.42%
2020-06-30 $63.63 Million $-1.47 Million -0.023x +96.12%
2019-06-30 $49.87 Million $-29.64 Million -0.594x -257.68%
2018-06-30 $48.63 Million $18.33 Million 0.377x +4715.74%
2017-06-30 $46.53 Million $-380.00K -0.008x -101.45%
2016-06-30 $59.66 Million $33.54 Million 0.562x +354.59%
2015-06-30 $75.78 Million $-16.73 Million -0.221x -6389.14%
2014-06-30 $98.55 Million $346.00K 0.004x +100.57%
2013-06-30 $106.83 Million $-66.18 Million -0.619x -229.90%
2012-06-30 $203.87 Million $-38.28 Million -0.188x -463.82%
2011-06-30 $240.33 Million $12.40 Million 0.052x +273.02%
2010-06-30 $170.08 Million $-5.07 Million -0.030x +42.95%
2009-06-30 $153.90 Million $-8.05 Million -0.052x +62.00%
2008-06-30 $130.76 Million $-17.99 Million -0.138x -248.81%
2007-06-30 $125.44 Million $11.60 Million 0.092x +129.31%
2006-06-30 $-80.86 Million $25.50 Million -0.315x +1.64%
2005-06-30 $-56.17 Million $18.02 Million -0.321x --

About Accuray Incorporated

NASDAQ:ARAY USA Medical Devices
Market Cap
$17.13 Million
Market Cap Rank
#25441 Global
#5384 in USA
Share Price
$0.14
Change (1 day)
-3.11%
52-Week Range
$0.12 - $1.45
All Time High
$7.46
About

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation t… Read more